5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Letter

Affiliations

¹ Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan. maeda-o@med.nagoya-u.ac.jp.
² Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.

Comment

Osamu Maeda et al. Clin Cancer Res. 2020.

. 2020 Jul 15;26(14):3889.

doi: 10.1158/1078-0432.CCR-20-0156.

¹ Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan. maeda-o@med.nagoya-u.ac.jp.
² Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.

No abstract available

Comment in

5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Response.
Sharma MR, Joshi SS, Kindler HL. Sharma MR, et al. Clin Cancer Res. 2020 Jul 15;26(14):3890. doi: 10.1158/1078-0432.CCR-20-1219. Clin Cancer Res. 2020. PMID: 32669272 Free PMC article. No abstract available.

Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing.
Joshi SS, Catenacci DVT, Karrison TG, Peterson JD, Zalupski MM, Sehdev A, Wade J, Sadiq A, Picozzi VJ, Amico A, Marsh R, Kozloff MF, Polite BN, Kindler HL, Sharma MR. Joshi SS, et al. Clin Cancer Res. 2020 Jan 1;26(1):18-24. doi: 10.1158/1078-0432.CCR-19-1483. Epub 2019 Sep 26. Clin Cancer Res. 2020. PMID: 31558477 Free PMC article. Clinical Trial.